Research and Markets: Rotavirus Infections Therapeutic Development - Pipeline Review & Analysis, H2 2015
November 27 2015 - 9:11PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/68dl3q/rotavirus) has
announced the addition of the "Rotavirus Infections - Pipeline
Review, H2 2015" report to their offering.
This report provides comprehensive information on the
therapeutic development for Rotavirus Infections, complete with
comparative analysis at various stages, therapeutics assessment by
drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in
the therapeutic development for Rotavirus Infections and special
features on late-stage and discontinued projects.
Key Topics Covered:
- The report provides a snapshot of the global therapeutic
landscape of Rotavirus Infections
- The report reviews key pipeline products under drug profile
section which includes, product description, MoA and R&D brief,
licensing and collaboration details & other developmental
activities
- The report reviews key players involved in the therapeutics
development for Rotavirus Infections and enlists all their major
and minor projects
- The report summarizes all the dormant and discontinued pipeline
projects
- A review of the Rotavirus Infections products under development
by companies and universities/research institutes based on
information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
- A detailed assessment of monotherapy and combination therapy
pipeline projects
- Coverage of the Rotavirus Infections pipeline on the basis of
target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline
products
Benefits of this Report:
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development for Rotavirus Infections
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Rotavirus Infections pipeline depth and focus of
Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Companies Mentioned:
- Beijing Minhai Biotechnology Co., Ltd
- Biological E. Limited
- CureVac GmbH
- Medicago Inc.
- Nanotherapeutics, Inc.
- SEEK Group
- Serum Institute of India Limited
- Shantha Biotechnics Limited
- Sinovac Biotech Ltd.
- Takeda Pharmaceutical Company Limited
For more information visit
http://www.researchandmarkets.com/research/68dl3q/rotavirus
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151127005413/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Infectious Diseases